Cargando…
Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune resp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458498/ https://www.ncbi.nlm.nih.gov/pubmed/35243821 http://dx.doi.org/10.1002/cnr2.1605 |
_version_ | 1784786309480448000 |
---|---|
author | Abhishek, Mahajan Renuka, Ashtekar Ujjwal, Agarwal Amit, Choudhari Vijay, Patil Vanita, Noronha Nandini, Menon Kumar, Prabash |
author_facet | Abhishek, Mahajan Renuka, Ashtekar Ujjwal, Agarwal Amit, Choudhari Vijay, Patil Vanita, Noronha Nandini, Menon Kumar, Prabash |
author_sort | Abhishek, Mahajan |
collection | PubMed |
description | Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality. |
format | Online Article Text |
id | pubmed-9458498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94584982022-09-12 Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report Abhishek, Mahajan Renuka, Ashtekar Ujjwal, Agarwal Amit, Choudhari Vijay, Patil Vanita, Noronha Nandini, Menon Kumar, Prabash Cancer Rep (Hoboken) Case Reports Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality. John Wiley and Sons Inc. 2022-03-03 /pmc/articles/PMC9458498/ /pubmed/35243821 http://dx.doi.org/10.1002/cnr2.1605 Text en © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Abhishek, Mahajan Renuka, Ashtekar Ujjwal, Agarwal Amit, Choudhari Vijay, Patil Vanita, Noronha Nandini, Menon Kumar, Prabash Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title_full | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title_fullStr | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title_full_unstemmed | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title_short | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
title_sort | atypical posterior reversible encephalopathy syndrome associated with lenvatinib therapy in a patient with metastatic thyroid cancer—a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458498/ https://www.ncbi.nlm.nih.gov/pubmed/35243821 http://dx.doi.org/10.1002/cnr2.1605 |
work_keys_str_mv | AT abhishekmahajan atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT renukaashtekar atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT ujjwalagarwal atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT amitchoudhari atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT vijaypatil atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT vanitanoronha atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT nandinimenon atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT kumarprabash atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport |